POLL: What would u like to try?

[JerkKILLER]

TweetHey guys,

if the following peptides were available domestic,
who would be interested in trying them out at the listed hypothetical prices?


Just curious




** For confidentiality reasons user names will NOT be shown on the poll.
But I'd like you to reply in the thread that "you'd be interested" (if u voted)
so I know how many votes are legit, and which ones are people trying to
be funny **

THX

[bionic redneck]

Tweet

Hey guys,

if the following peptides were available domestic,
who would be interested in trying them out at the listed hypothetical prices?


Just curious




** For confidentiality reasons user names will NOT be shown on the poll.
But I'd like you to reply in the thread that "you'd be interested" (if u voted)
so I know how many votes are legit, and which ones are people trying to
be funny **

THX

i voted for the PT-141... i read some interestin facts about it helpin in the sack.. so that sparked my interest..lol..hey at least i am honest about it..lol.. plus the rest cost more because of the dosage and which ones have to be taken together.. ex. igf and mgf

[iron_dawg]

Tweetnot very familiar with the whole peptide thing haven't had much time to research it...but how close is GHRP to the real thing if anyone could give me there input and maybe someone who has used it before.

[gator_mclusky]

TweetSome need to know what are Peptides and what they do.........

gator

[JerkKILLER]

TweetGood idea Gator, must have slipped my mind.

Some need to know what are Peptides and what they do.........

gator

[JerkKILLER]

TweetHere's the info on PT-141 aka Bremelanotide



Bremelanotide
(pronounced /ˌbrɛməˈlænɵtаɪd/ ( listen)) (formerly PT-141) is a compound under drug development by Palatin Technologies as a treatment for hemorrhagic shock and reperfusion injury. It functions by activating the melanocortin receptors MC1R and MC4R, to modulate inflammation and limiting ischemia. [1] It was originally developed for use in treating sexual dysfunction but this application was discontinued in 2008, after concerns were raised over adverse side effects of increased blood pressure.

Development

Originally, the peptide Melanotan II, that bremelanotide was developed from, was tested as a sunless tanning agent. In initial testing, Melanotan II did induce tanning but additionally caused sexual arousal and spontaneous erections as unexpected side effects in nine out of the ten original male volunteer test subjects.[2]

In studies, bremelanotide was shown to induce lordosis in an animal model [3] and was also effective in treating sexual dysfunction in both men (erectile dysfunction or impotence) and women (sexual arousal disorder). Unlike Viagra and other related medications, it does not act upon the vascular system, but directly increases sexual desire via the nervous system. [4]

A Phase III clinical trial was scheduled to begin in the first half of 2007, but was delayed until August 2007. On August 30, Palatin announced that the U.S. Food and Drug Administration had expressed serious concerns regarding the risk/benefit ratio of bremelanotide with regards to the side effect of increased blood pressure. The FDA stated that they would consider alternate uses for bremelanotide, including as a treatment for individuals who do not respond to more established ED treatments. However, On May 13, 2008, Palatin Technologies announced it "has discontinued development of Bremelanotide for the treatment of male and female sexual dysfunction" however they concurrently announced plans to develop it as a treatment for hemorrhagic shock instead. [5] The company additionally announced intentions to focus its attention on another compound, PL-6983, that causes lower blood pressure in animal models. [6]

Structure

Bremelanotide is a cyclic hepta-peptide lactam analog of alpha-melanocyte-stimulating hormone (alpha-MSH) that activates the melanocortin receptors MC3-R and MC4-R in the central nervous system. It has the amino acid sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH or cyclo-[Nle4, Asp5, D-Phe7, Lys10]alpha-MSH-(4-10). It is a metabolite of Melanotan II that lacks the C-terminal amide function.



See also

* Flibanserin
* Intrinsa
* Melanotan II


References

1. ^ Bremelanotide for Organ Protection and Related Indications, Palatin Technologies fact sheet. Retrieved on 2009-01-18.
2. ^ "Tanning drug may find new life as Viagra alternative" (HTML). CNN. 1999. http://www.cnn.com/HEALTH/men/9906/1...a.alternative/. Retrieved on 2007-09-16.
3. ^ Pfaus JG, Shadiack A, Van Soest T, Tse M, Molinoff P (July 2004). "Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist". Proc. Natl. Acad. Sci. U.S.A. 101 (27): 10201–4. doi:10.1073/pnas.0400491101. PMID 15226502.
4. ^ Vicki Mabrey (2006). "ABC News "The Business of Desire - Love Potion"" (HTML, Flash Video). ABC News. http://abcnews.go.com/Video/playerIndex?id=2712896. Retrieved on 2009-01-24.
5. ^ "Palatin Technologies announces new strategic objectives and reports third quarter 2008 financial results" (HTML). Palatin Technologies press release. 2008. http://palatin.com/news/news.asp?param=202. Retrieved on 2008-08-21.
6. ^ "Palatin Technologies Announces New Strategic Objectives". http://palatin.com/news/news.asp?ID=201. Retrieved on 2008-05-13.



Other links that may be of interest

* Palatin Technologies The company that developed bremelanotide. http://www.palatin.com/products/brem...e/overview.asp
* US 6,794,489 bremelanotide (PT-141) patent(Appl. No.:040547) http://www.google.com/patents?vid=6794489
* US 6,579,968 bremelanotide (PT-141) patent (Appl. No.:066501) http://www.pharmcast.com/Patents/Yr2...xual061703.htm
* www.melanotan.org

[JerkKILLER]

TweetHere's a small blurb about the CJC-1295
(I'll add more shortly, need to track down the info I misplaced, sorry)



CJC-1295
is a tetrasubtituted peptide of 29 amino acid length, primarily functioning as a growth hormone releasing hormone (GHRH) analog. It was innovated by ConjuChem, a Canadian biotechnology company.

One of the advantages of CJC-1295 over traditional GHRH or rHGH is its ability to bioconjugate with serum albumin, thus increasing its half-life and therapeutic window. It accomplishes this by using protecting groups around the amino acids of GHRH typically susceptible to enzymatic degradation.

ConjuChem initiated clinical trials for CJC-1295 during the mid-2000s. The objective of the drug was to treat visceral fat deposits in obese AIDS patients, as increased levels of exogenous HGH are presumed to increase lipolysis (fat loss). The trial was ultimately successful for most research subjects, but the drug's marketing stalled when three of the trial's patients suffered a myocardial infarction.

References

* Falutz, J et al. "A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation." AIDS. 2005 August 12;19(12):1279-87.

* Teichman, SL et al. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults." J Clin Endocrinol Metab. 2006 March 91(3):799-805. Epub 2005 December 13.

[JerkKILLER]

TweetHere's a bit about the GHRP-6, which is similar to the GHRP-2
(again, I'll post more info after I find it, sorry for the short explanation)


Growth hormone releasing hexapeptide (GHRP6)
is one of several synthetic met-enkephalin analogs that include unnatural D-amino acids, were developed for their growth hormone (GH) releasing activity and are called GH secretagogues. They lack opioid activity but are potent stimulators of GH release. These secretagogues are distinct from growth hormone releasing hormone (GHRH) in that they share no sequence relation and derive their function through action at a completely different receptor. This receptor was first called the GH secretagogue receptor, but now we know that the hormone ghrelin is this receptor's natural endogenous ligand and that these GH secetagouges act as synthetic mimetics of ghrelin.

The major side effect accompanied by the use of GHRP-6 or other GH secretagogues is a significant increase in appetite because secretagogues mimic the action of Ghrelin, a peptide which is released naturally in the lining of the stomach and increases hunger and gastric emptying.

GHRP-6, other secretagogues and ghrelin stimulate the anterior pituitary gland causing an increase in GH release. When natural GH secretion has been inhibited by long term abuse of synthetic GH, GHRP-6 may help to re-stimulate the natural production of GH. GHRP-6 may also affect the central nervous system by protecting neurons as well as increasing strength in a way very similar to the way certain steroids in the Dihydrotestosterone family do.

Claimed benefits of increased Growth Hormone levels through GHRP-6 stimulation include: an increase in strength, muscle mass and body fat loss, rejuvenation and strengthening of joints, connective tissue and bone mass. Enhanced GH secretion also leads to the liver secreting more IGF-1 (Insulin-Like Growth Factor 1), which is thought to be the primary anabolic mechanism of action for Growth Hormone.

Technical Data

It has also been discovered that when GHRP-6 and insulin are used simultaneously, GH response to GHRP-6 is increased (1). A recent study in normal mice showed significant differences in body composition, muscle growth, glucose metabolism, memory and cardiac function in the mice being administered the GHRP-6 (2). There are still many questions regarding this fairly new compound, scientists are hoping to gain a better clinical understanding of the peptide through further research over the next few years.

References

* Korbonits M, Goldstone AP, Gueorguiev M, Grossman AB (2004). "Ghrelin--a hormone with multiple functions". Frontiers in neuroendocrinology 25 (1): 27–68. doi:10.1016/j.yfrne.2004.03.002. PMID 15183037.

* {{Penlava, A, et. al. Effect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine, or hypoglycemia on GHRP-6-induced GH secretion in man.}}

* Template:J Clin Endocrinol Metab. 1993 Jan;76(1):168-71. Adeghate, E. & Ponery, A.S. (2002) Ghrelin stimulates insulin secretion from the pancreas of normal and diabetic rats. Journal of Neuroendocrinology, 14, 555560.

[nut]

TweetHey, just get me one that shuts down my myostatin gene and I'm game.

[iron_dawg]

Tweetthanks for the info JERK very informative.